The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
 
Hyojin Kim
No Relationships to Disclose
 
Sangjoon Choi
No Relationships to Disclose
 
Seokhwi Kim
No Relationships to Disclose
 
Jaehong Aum
Employment - Lunit
 
Sergio Pereira
Employment - Lunit
 
Seonwook Park
Employment - Lunit
Stock and Other Ownership Interests - Lunit; Lunit (Inst)
Research Funding - Lunit (Inst)
 
Minuk Ma
Employment - Lunit
 
Seunghwan Shin
Employment - Lunit; Merck Sharp & Dohme Corp.
Stock and Other Ownership Interests - Lunit
 
Kyunghyun Paeng
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit
 
Donggeun Yoo
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit
Patents, Royalties, Other Intellectual Property - Having several patents about medical AI developments in Lunit Inc.
 
Wonkyung Jung
Employment - Lunit
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Medpacto
Consulting or Advisory Role - Idience; Medpacto; Y-Biologics
 
Se-Hoon Lee
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Merck
Travel, Accommodations, Expenses - Novartis
 
Jin-haeng Chung
No Relationships to Disclose
 
Yoon-La Choi
No Relationships to Disclose
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; Hutchison China Meditech; Sanomics Limited
Stock and Other Ownership Interests - Aurora Tele-Oncology Platform; Hutchison China Meditech; Sanomics Limited
Honoraria - ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Fishawack Facilitate; InMed; Lilly; Merck Sharp & Dohme; Novartis; Origimed; Pfizer; Prime Oncology; Roche; Sanofi Aventis GmbH; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; CStone Pharmaceuticals; Curio Science; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Incyte; Inivata; IQvia; Lilly; Loxo; Lunit; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Puma Biotechnology; Roche; SFJ Pharmaceuticals Group; Takeda; Vertex; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)